Figure 6.

Change from baseline in fasting lipids at week 144 (A) and at weeks 96 and 144 (B) by National Cholesterol Education Program (NCEP) category. ^aNumber of participants with nonmissing fasting lipid data at baseline and week 144, excluding those with lipid-modifying agent administered at baseline (lipid data collected after initiation of a lipid-modifying agent were censored and a last observation carried forward method was applied). Use of lipid-modifying agents at baseline was similar between treatment groups (dolutegravir/lamivudine [DTG/3TC], 13%; tenofovir alafenamide [TAF]–based regimen, 15%). ^bPercentage change from baseline based on adjusted ratio (week 144 to baseline) in each group calculated from mixed-model repeated measures applied to change from baseline in log_e-transformed data adjusting for treatment, visit, baseline third agent class, age (continuous), body mass index (continuous), race, CD4⁺ cell count (continuous), log_e-transformed baseline value (continuous), treatment-by-visit interaction, and baseline value-by-visit interaction, with visit as the repeated factor. ^cNumbers of participants with nonmissing fasting lipid data at baseline and study week (week 96: DTG/3TC, n = 238; TAF- based regimen, n = 213; week 144: DTG/3TC, n = 243; TAF-based regimen, n = 230), excluding participants with lipid-modifying agent administered at baseline (lipid data collected after initiation of a lipid-modifying agent were censored and a last observation carried forward method was applied so that the last available fasted, on-treatment lipid value before initiation of a lipid-modifying agent was used). ^dNCEP categories at weeks 96 and 144 versus baseline. Abbreviations: CI, confidence interval; HDL, high-density lipoprotein; LDL, low-density lipoprotein; NA, not applicable; TC, total cholesterol; TGL, triglycerides.